Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022)

Veronica Dioverti; Zeinab El Boghdadly; Zainab Shahid; Alpana Waghmare; Maheen Z Abidi; Steven Pergam; Michael Boeckh; Sanjeet Dadwal; Mini Kamboj; Susan Seo; Roy F Chemaly; Genovefa A Papanicolaou

doi:10.1016/j.jtct.2022.09.002

Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022)

Transplant Cell Ther. 2022 Dec;28(12):810-821. doi: 10.1016/j.jtct.2022.09.002. Epub 2022 Sep 11.

Authors

Affiliations

¹ Assistant Professor of Medicine, Johns Hopkins University, Baltimore, Maryland. Electronic address: mdiover1@jhmi.edu.
² Assistant Professor of Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio.
³ Attending physician, Memorial Sloan Kettering Cancer Center, New York, New York.
⁴ Associate Professor of Pediatrics, University of Washington, Seattle, Washington; Fred Hutchinson Cancer Center, Seattle, Washington.
⁵ Assistant Professor of Medicine, University of Colorado, Denver, Colorado.
⁶ Professor, Fred Hutchinson Cancer Research Center, Associate Professor, University of Washington, Seattle, Washington.
⁷ Fred Hutchinson Cancer Center, Seattle, Washington; Professor of Medicine, University of Washington, Seattle, Washington.
⁸ Professor of Medicine, City of Hope, Duarte, California.
⁹ Associate Professor of Medicine, Weill Cornell Medical College, New York, New York; Memorial Sloan Kettering Cancer Center, New York, New York.
¹⁰ Memorial Sloan Kettering Cancer Center, New York, New York; Professor of Clinical Medicine, Weill Cornell Medical College, New York, New York.
¹¹ Professor of Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas.
¹² Memorial Sloan Kettering Cancer Center, New York, New York; Professor of Medicine, Weill Cornell Medical College, New York, New York.

Abstract

This document is intended as a guide for diagnosis and management of Coronavirus Disease 2019 (COVID-19), caused by the virus SARS-CoV-2, in adult and pediatric HCT and cellular therapy patients. This document was prepared using available data and with expert opinion provided by members of the (ASTCT) Infectious Diseases Special Interest Group (ID-SIG) and is an update of pervious publication. Since our original publication in 2020, the NIH and IDSA have published extensive guidelines for management of COVID-19 which are readily accessible ( NIH Guidelines , IDSA Guidelines ). This update focuses primarily on issues pertaining specifically to HCT/cellular therapy recipients. Information provided in this manuscript may change as new information becomes available.

Keywords: COVID-19; Cellular therapy; Hematopoietic cell transplantation; SARS-CoV-2.

Publication types

Practice Guideline

MeSH terms

Adult
COVID-19* / therapy
Cell- and Tissue-Based Therapy
Child
Hematopoietic Stem Cell Transplantation*
Humans
SARS-CoV-2

Grants and funding

K23 AG073534/AG/NIA NIH HHS/United States